Navigation Links
Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, Former Head of Roche Molecular Diagnostics
Date:8/24/2017

Stemina Biomarker Discovery Inc. today announced that Heiner Dreismann, PhD, former head of Roche Molecular Diagnostics, has joined the board of directors to bring his extensive experience in commercialization strategy to the company as it prepares to go to market in early 2018 with its autism diagnostic test panel. Stemina, through its neurological disorders division, NeuroPointDX, is transforming diagnosis and more precise treatment of neurological disorders using its proprietary metabolomics platform technology to diagnose disorders based on the patient’s metabolism. The company’s proprietary technology is already being implemented in the largest clinical study ever conducted of the metabolism of children with autism spectrum disorder (ASD), the Children’s Autism Metabolome Project (CAMP).

Dr. Dreismann, former President and CEO of Roche Molecular Systems and Global Head of Business Development for Roche Diagnostics, led the strategic vision process and established a new strategic architecture for Roche Diagnostics. “We are so pleased that Dr. Dreismann has agreed to join our board to advise us on commercialization strategy for our diagnostic products,” said Stemina’s CEO, Elizabeth Donley. “NeuroPointDX will revolutionize the way autism and other neurological disorders are diagnosed and treated by measuring differences in metabolism of children with ASD across the spectrum.”

“I am excited to join the Stemina Board of Directors as the company has developed and is poised to commercialize a first-in-class, unique product for diagnosis of ASD in children as young as 18 months,” said Dreismann. “Neurological disorders are notoriously difficult to diagnose and treat. NeuroPointDX will greatly improve the precision of diagnosing these disorders.”

“Neurological disorders like autism and schizophrenia, which have historically been defined based on behavioral findings, are now recognized to be comprised of a variety of metabolic and genetic subtypes. Using our proprietary technology, we have identified a series of subtypes of ASD and other neuro-developmental disorders. We have validated a number of these through the CAMP study,” Donley said. “We expect that our approach will provide important information for diagnosis and more precise treatment as well as opportunities to collaborate with drug developers on targeted therapies and clinical trials.”

The CAMP study has enrolled more than 900 patients to date. Enrollment of children ages 18 to 48 months comprised of three groups of children: those with ASD, others with developmental delay but not ASD, and typically-developing children, continues at eight sites across the country. Visit https://neuropointdx.com/camp/ for more information. The CAMP study has validated a panel of metabolic subtypes previously identified in pilot studies of banked blood samples at the MIND Institute at UC-Davis and the Arkansas Children’s Hospital Research Institute.

STEMINA BIOMARKER DISCOVERY:
Stemina Biomarker Discovery was founded in 2007 and is located in Madison, Wisconsin. Stemina delivers the only human cell based test for screening drugs and chemical compounds for their potential to cause birth defects if a woman is exposed during pregnancy.

Visit Stemina at http://www.stemina.com/.

ABOUT NEUROPOINTDX:
NeuroPointDX is a division of Stemina Biomarker Discovery. NeuroPointDX uses its metabolomics platform and proprietary biomarker database to diagnose, treat and develop new therapies for neurological disorders.

Visit NeuroPointDX at http://neuropointdx.com/.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14614855.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. KCAS Bioanalytical and Biomarker Services Welcomes Director of Large Molecule and Biomarker Services
2. Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
3. DiaSorin Showcases the Benefits of Utilizing Available Biomarkers to Tailor and Individualize Therapy in Diabetes
4. Biologist Discovers Biomarker That Verifies Commitment in Men
5. Agilent Offers Clinical Research Applications of Accelerated Data Workflows for Biomarker Discovery in Cystic Fibrosis Research
6. Biomarkers in Concussion Management to be Key Topic at Arrowhead Publishers’ 7th Annual Traumatic Brain Injury Conference
7. KCAS Bioanalytical and Biomarker Services Now Offers Ultra-Sensitive Validated Assay for Nicotine Studies
8. BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
9. GeneNews Launches Blood-Based, Biomarker Test for Breast Cancer Risk Assessment
10. FDA Grants de novo Clearance for the Brain Sentinel® Monitoring and Alerting System, Bringing a New Biomarker to Help People With Epilepsy
11. Biomarkers Market Worth 53.34 Billion USD by 2021
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):